Compare DexCom, Inc. (DXCM) vs Eversource Energy (D/B/A) Common Stock (ES) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Eversource Energy (D/B/A) Common Stock — how do they compare? DexCom, Inc. trades at $84.41 (market cap $32.09B), while Eversource Energy (D/B/A) Common Stock trades at $66.63 (market cap $24.77B). The key difference: DexCom, Inc. is the larger of the two by market cap, and Eversource Energy (D/B/A) Common Stock pays a 4.79% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Eversource Energy (D/B/A) Common Stock for 0 Days on average.
| DXCM | ES | |
|---|---|---|
Market Cap | $32.09B | $24.77B |
Volume | 3,819,730 | 3,738,127 |
Sector | Health | Utilities |
52-Week High | $92.34 | $76.21 |
52-Week Low | $54.84 | $63.28 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | $31.54B | $54.84B |
Dividend Yield | — | 4.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $83.47, down 2.85% on the day, amid a generally bullish technical and fundamental backdrop. The stock shows strong revenue growth, with 2025 revenue reaching $4.66 billion and net income of $836.3 million, and has consistently beaten earnings expectations. Analyst consensus is strongly positive with a price target of $96.14, and recent news highlights expansion opportunities in the Type 2 diabetes CGM market.
The outlook for DXCM is positive, driven by solid financial performance and market expansion potential. Key opportunities include growing adoption of its CGM systems, while risks involve competitive pressures and reimbursement challenges. The stock presents a compelling case for growth-oriented investors, supported by strong analyst backing and institutional interest.
Eversource Energy (ES) trades at $65.75, down 0.53% with neutral technical signals. The company maintains solid fundamentals with a 17.08 P/E ratio, 84.95% gross margin, and recent earnings beats in Q4 2025 and Q1 2026. Analyst consensus targets $73.75 with 31% buy ratings, while the company progresses on grid modernization projects and regulatory clarity in Connecticut.
ES offers steady utility exposure with 4.5% dividend yield and $26.5B capex plan supporting growth, though Q2 2026 earnings miss and regulatory uncertainty pose near-term risks. The stock presents value for income investors seeking regulated utility stability with infrastructure upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Eversource Energy (D/B/A) Common Stock
Eversource Energy is a regulated utility holding company delivering electricity, natural gas, and water to customers in Connecticut, Massachusetts, and New Hampshire. It operates through electric distribution and transmission, natural gas distribution, and water distribution segments, via subsidiaries including CL&P, NSTAR, PSNH, Yankee Gas, and Aquarion.
Read more on ES →
